Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation.

Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, Uehlinger C, Kasas A, Amey M, Jonzier-Perey M.

J Clin Psychopharmacol. 1996 Aug;16(4):307-14.

PMID:
8835706
2.

[Treatment of resistant depression with the citalopram-lithium combination. Methodology of a double-blind multicenter study and preliminary results].

Souche A, Montaldi S, Uehlinger C, Kasas A, Reymond MJ, Reymond P, Baumann P, Dufour H.

Encephale. 1991 May-Jun;17(3):213-9. French.

PMID:
1864255
3.

CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.

Tamminga WJ, Wemer J, Oosterhuis B, Weiling J, Wilffert B, de Leij LF, de Zeeuw RA, Jonkman JH.

Eur J Clin Pharmacol. 1999 May;55(3):177-84.

PMID:
10379632
4.

Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.

Koyama E, Tanaka T, Chiba K, Kawakatsu S, Morinobu S, Totsuka S, Ishizaki T.

J Clin Psychopharmacol. 1996 Aug;16(4):286-93.

PMID:
8835703
5.

Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes.

Rochat B, Amey M, Gillet M, Meyer UA, Baumann P.

Pharmacogenetics. 1997 Feb;7(1):1-10.

PMID:
9110356
6.
7.

Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups.

Britzi M, Bialer M, Arcavi L, Shachbari A, Kapitulnik T, Soback S.

Ther Drug Monit. 2000 Oct;22(5):510-6.

PMID:
11034254
8.

Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.

Spigset O, Granberg K, Hägg S, Norström A, Dahlqvist R.

Eur J Clin Pharmacol. 1997;52(2):129-33.

PMID:
9174682
9.

Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation.

Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P.

Psychopharmacology (Berl). 1996 Dec;128(4):421-5.

PMID:
8986013
10.

Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin.

von Bahr C, Ursing C, Yasui N, Tybring G, Bertilsson L, Röjdmark S.

Eur J Clin Pharmacol. 2000 May;56(2):123-7.

PMID:
10877005
11.

Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test.

Eap CB, Bondolfi G, Zullino D, Bryois C, Fuciec M, Savary L, Jonzier-Perey M, Baumann P.

Ther Drug Monit. 2001 Jun;23(3):228-31.

PMID:
11360030
12.

Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline.

Baumann P, Meyer JW, Amey M, Baettig D, Bryois C, Jonzier-Perey M, Koeb L, Monney C, Woggon B.

Ther Drug Monit. 1992 Feb;14(1):1-8.

PMID:
1546384
13.
14.

Routine therapeutic drug monitoring in patients treated with 10-360 mg/day citalopram.

Le Bloc'h Y, Woggon B, Weissenrieder H, Brawand-Amey M, Spagnoli J, Eap CB, Baumann P.

Ther Drug Monit. 2003 Oct;25(5):600-8.

PMID:
14508384
15.

Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.

Hägg S, Spigset O, Dahlqvist R.

Br J Clin Pharmacol. 2001 Feb;51(2):169-73.

16.

Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism.

Guttendorf RJ, Britto M, Blouin RA, Foster TS, John W, Pittman KA, Wedlund PJ.

Br J Clin Pharmacol. 1990 Apr;29(4):373-80.

17.
18.

Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.

Kuhn UD, Kirsch M, Merkel U, Eberhardt AM, Wenda B, Maurer I, Härtter S, Hiemke C, Volz HP, Balogh A.

Int J Clin Pharmacol Ther. 2007 Jan;45(1):36-46.

PMID:
17256449
19.

Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes.

Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, Tani M, Yamamoto T, Ishizaki T, Kuroiwa Y.

J Pharmacol Exp Ther. 1997 Feb;280(2):927-33.

20.

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.

Tsai MH, Lin KM, Hsiao MC, Shen WW, Lu ML, Tang HS, Fang CK, Wu CS, Lu SC, Liu SC, Chen CY, Liu YL.

Pharmacogenomics. 2010 Apr;11(4):537-46. doi: 10.2217/pgs.09.168.

PMID:
20350136

Supplemental Content

Support Center